{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:04Z","timestamp":1791397384428,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,8,25]],"date-time":"2010-08-25T00:00:00Z","timestamp":1282694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Peripheral T\u2010Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B\u2010cell lymphomas. Despite unsatisfactory results with the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, it remains the reference front\u2010line therapy in these diseases, but has not been challenged in phase III trials. The Groupe Ouest Est d\u2019Etude des Leuc\u00e9mies et Autres Maladies du Sang (GOELAMS) devised an alternative therapeutic schedule including etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine (VIP\u2010reinforced\u2010ABVD; VIP\u2010rABVD) and compared it to CHOP\/21 as front\u2010line treatment in non\u2010cutaneous PTCL. All newly diagnosed patients were eligible. The primary objective was to improve the 2\u2010year event\u2010free survival (EFS) rate. Secondary objectives were to compare the response rate, overall survival, and toxicities as well as identify prognostic factors. Eighty\u2010eight patients were identified between 1996 and 2002<jats:bold>.<\/jats:bold> Both arms were well balanced for patients\u2019 characteristics in terms of histological and clinical presentation. No significant difference was observed between the two arms in terms of 2\u2010year EFS. Anaplastic large cell lymphoma type and Ann Arbor stage I\u2013II were identified as two independent favourable prognostic factors influencing survival. VIP\u2010rABVD was not superior to CHOP\/21 in terms of EFS as first\u2010line treatment of PTCL, confirming that CHOP\/21 remains the reference regimen in these lymphomas.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08329.x","type":"journal-article","created":{"date-parts":[[2010,8,29]],"date-time":"2010-08-29T19:11:48Z","timestamp":1283109108000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Upfront VIP\u2010reinforced\u2010ABVD (VIP\u2010rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS\u2010LTP95"],"prefix":"10.1111","volume":"151","author":[{"given":"Audrey","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Peoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Casassus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Desablens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houchingue","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Foussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Jaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Vilque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Thyss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Maloisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh409"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702867"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non\u2010Hodgkin\u2019s lymphoma. The non\u2010Hodgkin\u2019s lymphoma classification project","volume":"89","author":"Chan W.C.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.004"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.401.401","article-title":"Dose\u2010Dence induction followed by autologous stem cell transplant (ASCT) as first\u2010line treatment in peripheral T cell lymphomas (PTCL) \u2013 A phase II study of Nordic lymphoma group (NLG)","volume":"108","author":"D\u2019amore F.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3913"},{"key":"e_1_2_7_12_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA)","volume":"92","author":"Gisselbrecht C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_13_1","first-page":"104","article-title":"Confirmation a long terme.de l\u2019efficacite du schema VIP\/ABVD dans le traitement des lymphomes T p\u00e9riph\u00e9riques non anaplasiques et anaplasiques","volume":"6","author":"Gressin R.","year":"2000","journal-title":"Hematologie"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686323"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2008.1.289"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609045720"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950160104"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06658.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3068"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701202"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl466"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.267"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_7_30_1","volume-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh427"},{"key":"e_1_2_7_32_1","first-page":"790","article-title":"Anaplastic large cell lymphoma Hodgkin\u2019s\u2010like: a randomized trial of ABVD versus MACOP\u2010B with and without radiation therapy","volume":"92","author":"Zinzani P.L.","year":"1998","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08329.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08329.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:35:02Z","timestamp":1697423702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08329.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,25]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08329.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08329.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,25]]},"assertion":[{"value":"2010-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}